Bausch Health (BHC) Stock
Key stats
- Market cap
- $3.33B
- Price / Earnings ratio
- -2.4x
- EPS (TTM)
- -$2.96
- Volume
- Loading
- 52-week high
- $8.00
- 52-week low
- $4.33
- EPS vs analyst estimate
- +9.4%Q3 FY25 · $1.16 vs $1.06
Source: third-party data provider, as of October 31, 2026
EPS estimate: analyst consensus
Compare with BHC
Recent news

BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
BHC

Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
BHC

Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
BHC

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
BHC
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 87.75
- MACD 12/26/9
- 0.35
- EMA 9 of MACD
- 0.15
- MACD histogram
- 0.20
- SMA 50
- $6.21
- Price above SMA 50
- EMA 50
- $6.20
- Price above EMA 50
- SMA 200
- $5.70
- Price above SMA 200
- EMA 200
- $6.01
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 29, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.75 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
BHC

Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
BHC

Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
BHC

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
BHC

BHC Q3 Earnings Preview: Here's What You Should Know
BHC Q3 Earnings Preview: Here's What You Should Know
BHC

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
BHC

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
BHC

Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
BHC

Best Value Stocks to Buy for September 22nd
Best Value Stocks to Buy for September 22nd
BHC

4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
BHC
News tone: automated (AI) classification of the article's content, not a price prediction.
About Bausch Health
Bausch Health Companies Inc. is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas J. Appio | CEO & Director | 1962 |
| Mr. Jean-Jacques Charhon | Executive VP & CFO | 1965 |
| Mr. Mirza Dautbegovic | Executive VP & COO | — |
| Ms. Seana Carson | Executive VP & General Counsel | 1973 |
| Ms. Aimee J. Lenar | President of US Pharma | 1976 |
| Mr. Steven H. Lee | Senior VP, Controller & Chief Accounting Officer | 1971 |
| Mr. Garen Sarafian | VP & Head of Investor Relations | — |
| Ms. Kathleen Fitzpatrick | Executive VP and Chief HR & Communications Officer | — |
| Mr. Cees Heiman | Senior Vice President of Europe & Canada | — |
| Ms. Jiny Kim M.B.A. | Senior Vice President of Solta Medical | 1977 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of October 31, 2026
Technical indicators
- RSI 14
- 87.75
- MACD 12/26/9
- 0.35
- EMA 9 of MACD
- 0.15
- MACD histogram
- 0.20
- SMA 50
- $6.21
- Price above SMA 50
- EMA 50
- $6.20
- Price above EMA 50
- SMA 200
- $5.70
- Price above SMA 200
- EMA 200
- $6.01
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 29, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $8.00
- Average
- $9.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -16.4 | +20.0 | ||||||||||
| 2022 | -11.6 | -4.0 | -2.5 | -17.5 | -48.4 | -12.6 | -45.8 | +30.1 | +4.6 | -7.5 | +1.9 | -18.4 |
| 2023 | +22.6 | +18.9 | -12.1 | -5.5 | +9.3 | -2.4 | +24.2 | -11.9 | -2.8 | -16.2 | +0.8 | +9.0 |
| 2024 | +0.9 | +17.7 | +7.3 | -15.8 | -25.0 | +10.1 | -15.0 | -2.8 | +34.4 | +11.2 | -14.4 | +3.1 |
| 2025 | -6.4 | +2.2 | -9.8 | -15.2 | -14.5 | +48.7 | -13.3 | +29.9 | -16.0 | +6.0 | -6.8 | -1.4 |
| 2026 | -20.4 | +3.0 | -9.2 | +2.5 | -5.1 | -7.2 | +44.4 | -9.0 | -9.9 | +55.5 |



